Clinical trials · Rochester, NY
Lymphoma clinical trials in Rochester
We’re tracking 31 recruiting lymphoma studies with a site in or near Rochester — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Rochester
- NCT04840602RecruitingPhase 2
Venetoclax plus rituximab versus standard Waldenstrom treatment
This trial tests whether adding venetoclax to rituximab works better than standard treatment options for Waldenstrom’s macroglobulinemia (WM). It’s for adults whose WM needs treatment and who meet specific blood, organ, infection, and medication safety requirements.
Rochester, New YorkAges 18 years+ - NCT05675410RecruitingPhase 3
Testing two-drug treatment versus standard for Hodgkin lymphoma
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
Rochester, New YorkAges 5–60 - NCT06337318RecruitingPhase 3
Comparing two drugs for low-tumor burden follicular lymphoma
This trial compares a standard drug called rituximab to a newer medicine called mosunetuzumab for people with a slow-growing type of lymphoma that is not causing many symptoms. The goal is to see if mosunetuzumab works better and has fewer side effects.
Rochester, New YorkAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Rochester, New YorkAges 18 years+ - NCT04803201RecruitingPhase 2
Adding new drugs to usual treatment for peripheral T-cell lymphoma
This trial tests whether adding one of two experimental drugs to the standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma, a rare blood cancer. It aims to see if the combination is safe and effective.
Rochester, New YorkAges 18 years+ - NCT06002828Recruiting
Social and genetic factors in young adult cancer survivors
This study looks at how social and genetic factors affect the health and quality of life of young adults who have survived Hodgkin or non-Hodgkin lymphoma. It may help doctors better support survivors after treatment.
Rochester, New YorkAges 18 years+ - NCT07226843RecruitingPhase 1
Study of a new drug for adults with certain blood cancers
This trial tests a new drug, LY4584180, for adults with several types of non-Hodgkin lymphoma who have already had at least two prior treatments. The goal is to see if the drug can help shrink tumors and stop the cancer from growing.
Rochester, New YorkAges 18 years+ - NCT04269902RecruitingPhase 3
Early treatment check for high-risk CLL/SLL
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
Rochester, New YorkAges 18 years+ - NCT06634589RecruitingPhase 1/Phase 2
Combination therapy for relapsed B-cell blood cancers
This study tests new drug combinations for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. It aims to see if these combos are safe and can help fight the cancer.
Rochester, New YorkAges 18 years+ - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Rochester, New YorkAges 12 months–25 years - NCT06973187RecruitingPhase 3
Comparing two drugs for CLL or SLL after prior treatment
This trial tests a new drug (BGB-16673) against another drug (pirtobrutinib) for people with CLL or SLL that hasn't responded to or has come back after a prior BTK inhibitor treatment. The goal is to see which drug is more effective and safe.
Rochester, New YorkAges 18 years+ - NCT03758989RecruitingPhase 2
PET-guided treatment and monitoring for limited-stage lymphoma
This Phase 2 study tests a treatment approach guided by PET scans, plus non-invasive monitoring, for adults with limited-stage diffuse large B-cell lymphoma (a type of lymphoma). It may help by tailoring therapy based on scan and other follow-up information, aiming for better outcomes with fewer invasive steps.
Rochester, New YorkAges 18 years+ - NCT04989803RecruitingPhase 1/Phase 2
Tested two lymphoma cell therapies for relapsed or resistant cancer
This trial studies two investigational cell therapies (KITE-363 or KITE-753) in people whose B-cell lymphoma has returned or did not respond to prior treatment. The goal is to see how safe the treatments are and how well they can shrink the lymphoma.
Rochester, New YorkAges 18 years+ - NCT06084936RecruitingPhase 3
Glofitamab alone vs other treatments for mantle cell lymphoma
This trial tests a new drug called glofitamab to see if it works better than other standard treatments for people with mantle cell lymphoma that has come back or not responded to previous therapy. It is for patients who have already tried a BTK inhibitor and at least one other treatment.
Rochester, New YorkAges 18 years+ - NCT06098430Recruiting
Quality of life in NLPHL patients
This study looks at how people with a rare type of Hodgkin lymphoma (NLPHL) feel about their health and quality of life. By filling out surveys, you can help doctors understand what really matters to patients like you.
Rochester, New YorkAges 8 years+ - NCT06828991RecruitingPhase 2
Mosunetuzumab for older DLBCL patients with residual ctDNA
This trial tests whether adding a targeted immunotherapy drug called mosunetuzumab after standard chemotherapy can help older adults with DLBCL who still have tiny traces of cancer DNA in their blood. If you qualify, the goal is to reduce the chance of the cancer coming back.
Rochester, New YorkAges 70 years+ - NCT01790152Recruiting
Dexrazoxane study to monitor heart damage in cancer survivors
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Rochester, New YorkAges Any age - NCT03016806Recruiting
Umbilical cord blood transplant from unrelated donors
This trial studies transplanting healthy blood-forming cells from an umbilical cord blood donor who is not related to you. It may help people with certain blood cancers, immune disorders, or other serious diseases when a standard transplant plan is needed.
Rochester, New YorkAges 2 months–75 years - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
Rochester, New YorkAges Any age - NCT04315324RecruitingPhase 1/Phase 2
Test drug OBI-3424 for relapsed T-cell blood cancer
This trial tests OBI-3424, an investigational medicine, in adults and children with relapsed or hard-to-treat T-cell acute leukemia or certain T-cell lymphoma. It may help by shrinking cancer when standard treatments have not worked.
Rochester, New YorkAges 12 years+ - NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
Rochester, New YorkAges 18 years+ - NCT04669171RecruitingPhase 1/Phase 2
Vaccine treatment for slow-growing lymphoma, alone or combined
This trial tests a new vaccine medicine (EO2463) to treat indolent non-Hodgkin lymphoma (slow-growing lymphoma), either by itself or with other treatment. It may help your immune system recognize and attack lymphoma cells.
Rochester, New YorkAges 18 years+ - NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Rochester, New YorkAges 18 years+ - NCT05006482RecruitingPhase 3
Geriatric education and care support for older cancer survivors
This study tests whether a structured health education and “older adult care” approach—done with your oncology team—can improve support for people after cancer. It includes older cancer survivors and a chosen caregiver, using in-person or video visits for follow-up.
Rochester, New YorkAges 18 years+
Hear when a new Lymphoma trial opens near Rochester, NY
We’ll email you when one opens near Rochester, NY — at most once a week, no account needed, unsubscribe anytime.
Lymphoma trials in other cities
Where these studies are running near Rochester
Institutions with a site for the recruiting lymphoma studies listed above.
- University of Rochester · 17 studies
- Wilmot Cancer Institute at Webster · 7 studies
- Wilmot Cancer Institute · 4 studies
- University of Rochester Medical Center · 2 studies
- Highland Hospital
- Pluta Cancer Center
- Rochester General Hospital
- Strong Memorial Hospital
What taking part in a lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting lymphoma studies in New York.
Common questions
- Are there lymphoma clinical trials near Rochester?
- Yes. We're currently tracking 31 recruiting lymphoma studies with a site near Rochester, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lymphoma study near Rochester?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Rochester to take part?
- Not necessarily. These studies have a site near Rochester, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lymphoma studies open near Rochester regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.